| Year |
Citation |
Score |
| 2010 |
Mitchell C, Yacoub A, Hossein H, Martin AP, Bareford MD, Eulitt P, Yang C, Nephew KP, Dent P. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biology & Therapy. 10: 903-17. PMID 20855960 DOI: 10.4161/Cbt.10.9.13273 |
0.691 |
|
| 2009 |
Martin AP, Mitchell C, Rahmani M, Nephew KP, Grant S, Dent P. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biology & Therapy. 8: 2084-96. PMID 19823038 DOI: 10.4161/Cbt.8.21.9895 |
0.733 |
|
| 2009 |
Dahan S, Roth-Walter F, Martin AP, Arnaboldi P, Mayer L. Lymphoepithelial interactions: a new paradigm. Annals of the New York Academy of Sciences. 1165: 323-6. PMID 19538323 DOI: 10.1111/J.1749-6632.2009.04061.X |
0.337 |
|
| 2009 |
Martin AP, Park MA, Mitchell C, Walker T, Rahmani M, Thorburn A, Häussinger D, Reinehr R, Grant S, Dent P. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Molecular Pharmacology. 76: 327-41. PMID 19483105 DOI: 10.1124/Mol.109.056309 |
0.762 |
|
| 2009 |
Park MA, Walker T, Martin AP, Allegood J, Vozhilla N, Emdad L, Sarkar D, Rahmani M, Graf M, Yacoub A, Koumenis C, Spiegel S, Curiel DT, Voelkel-Johnson C, Grant S, et al. MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism. Molecular Cancer Therapeutics. 8: 1280-91. PMID 19417161 DOI: 10.1158/1535-7163.Mct-09-0073 |
0.729 |
|
| 2008 |
Park MA, Zhang G, Martin AP, Hamed H, Mitchell C, Hylemon PB, Graf M, Rahmani M, Ryan K, Liu X, Spiegel S, Norris J, Fisher PB, Grant S, Dent P. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biology & Therapy. 7: 1648-62. PMID 18787411 DOI: 10.4161/Cbt.7.10.6623 |
0.723 |
|
| 2008 |
Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, Curiel DT, Yacoub A, Graf M, Lee R, Roberts JD, Fisher PB, Grant S, Dent P. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5385-99. PMID 18765530 DOI: 10.1158/1078-0432.Ccr-08-0469 |
0.737 |
|
| 2008 |
Martin AP, Miller A, Emad L, Rahmani M, Walker T, Mitchell C, Hagan MP, Park MA, Yacoub A, Fisher PB, Grant S, Dent P. Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation. Molecular Pharmacology. 74: 807-22. PMID 18544666 DOI: 10.1124/Mol.108.047365 |
0.737 |
|
| 2008 |
Hamed H, Mitchell C, Park MA, Hanna D, Martin AP, Harrison B, Hawkins W, Curiel DA, Fisher PB, Grant S, Yacoub A, Hagan MP, Dent P. Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo. Cancer Biology & Therapy. 7: 587-93. PMID 18379195 DOI: 10.4161/Cbt.7.4.5543 |
0.723 |
|
| 2006 |
Grisotto MG, Garin A, Martin AP, Jensen KK, Chan P, Sealfon SC, Lira SA. The human herpesvirus 8 chemokine receptor vGPCR triggers autonomous proliferation of endothelial cells. The Journal of Clinical Investigation. 116: 1264-73. PMID 16604194 DOI: 10.1172/Jci26666 |
0.359 |
|
| Show low-probability matches. |